Emergence client, BioTraceIT™ is hiring…

BioTraceIT is actively seeking applications from qualified candidates for a Senior Data Scientist & Blockchain Developer.

BioTraceIT values the capacity to improve medical care and interventions by quantifying pain ultimately impacting quality of life and wellness.

BioTraceIT focuses on novel technologies at the cutting edge of wearable health care. We deem new solutions as paramount to new paradigms. By measuring pain, we quantify wellness.

BioTraceIT is currently seeking a Senior Data Scientist with blockchain development experience within Healthcare IoT to ensure that IoT medical device data is integrated with electronic medical records and individual patient data sources by leveraging machine learning / AI for predictive analytics. Block chain development is required for data security architecture.

The ideal candidate will have expertise in software development including: coding, analytics, EMR, NLP, and medical acumen and an understanding of the complex healthcare systems and treatment areas (common practice and guidelines) as well as a focus on big data analytics and blockchain.

This position will be located in Charlottetown, Prince Edward Island. Click here to apply.

Emergence client, Nautilus Biosciences, a wholly-owned subsidiary of Croda International Plc (“Croda”), has celebrated its official opening as the “Centre of Innovation for Marine Biotechnology“.

See:  Nautilus Biosciences Officially Opens Its Expanded UPEI-Based Facility as Croda’s Centre of Innovation for Marine Biotechnology and High-tech robot to help with bioscience research at UPEI

Ribbon cutting – for the new Croda Centre of Innovation for Marine Biotechnology at UPEI, Charlottetown, PEI

A ribbon-cutting event, held at the Regis and Joan Duffy Research Centre at the University of Prince Edward Island, included senior representatives from Croda, as well as the President of UPEI, Dr. Alaa Abd-El-Aziz, Provincial Minister of Health and Wellness, Robert Mitchell, and members of PEI’s bioscience business and research community.

The acquisition of Nautilus early in 2018, together with continued investment by Croda to establish their new Centre of Innovation for Marine Biotechnology, is designed to accelerate the company’s research and product development program that aims to identify sustainable, natural sources of functional ingredients for a broad range of personal, health and crop care ingredients for its global customers.

Sandra Breene, President, Personal Care at Croda

“Croda is a company that values innovation and invests in new technologies to deliver value to our customers today and in the future,” Sandra Breene, President, Personal Care at Croda International told us.

“The acquisition of Nautilus is part of our journey to expand from being a manufacturer of speciality chemicals into an organisation that embraces biotechnology as the answer to many of our customers and the consumer needs for new actives in a truly sustainable way.”

The opening of the expanded Nautilus facility follows Croda making a significant investment in an automated high-throughput screening system that can dramatically increase the discovery of novel products derived from the marine microbe library.

Dr. Russ Kerr, Canada Research Chair in Marine Natural Products at UPEI

Professor Russell Kerr, , and founder of Nautilus Biosciences, has worked since 2007 to establish the Marine Microbial Library at UPEI, collecting marine samples from the oceans of Canada and around the world and developing techniques to assess their value as sources of sustainable chemistry. A multi-year collaboration with Croda demonstrated to them the potential of marine natural products in providing new chemical entities.

“This is an exciting day for us,” Dr. Kerr told us. “We’ve been very fortunate to build on a relationship with a multinational speciality chemical company that values growth through sustainable innovation – enhancing our ability to discover even more marine microbes as a potential source of commercial ingredients. We are very proud to be opening this Centre of Innovation in Marine Biotechnology in Prince Edward Island.”

PEI’s Minister of Health and Wellness, Robert Mitchell

Nautilus is a successful spinout from the University of Prince Edward Island. Nautilus has exclusive access to the Marine Microbial Library which is based at the University.

“To see Dr. Kerr take a great idea, collaborate with other faculty and our students, and develop this idea into an entrepreneurial opportunity like Nautilus Biosciences is so wonderful, and what the University is here to support,” said Dr. Alaa Abd-El-Aziz, President and Vice-Chancellor of the University of Prince Edward Island.

About Croda

Established in 1925, Croda is the name behind high performance ingredients and technologies in some of the world’s biggest and most successful brands: creating, making and selling speciality chemicals that are relied on by industries and consumers everywhere. They have a network of over 4,200 passionate and committed employees, working together as one global team across manufacturing sites and offices in 36 countries. Croda is a FTSE100 company with a flexible structure that allows them to focus on developing and delivering innovative, sustainable ingredients that their customers can build on in: Personal Care, Health Care, Crop Care, Polymer Additives, Lubricants, Coatings & Polymers, Geo Tech, Home Care and Industrial Specialities. http://www.croda.com/

About Nautilus Biosciences Croda
Nautilus Biosciences Canada Inc. is a technology-rich marine biotechnology company based in Charlottetown, Prince Edward Island, Canada. Founded in 2007 by Dr. Russell Kerr, Nautilus focuses on using marine microbial biodiversity to discover novel actives and materials.

Dr. Joseph Gabriele, co-founder of Emergence client, Delivra from Hamilton, Ontario and Charlottetown, PEI, has walked away with the 2018 EY Entrepreneur Of The Year award in the Health Care category in the Ontario region.

Dr. Joe Gabriele

EY Entrepreneur Of The Year is the world’s most prestigious business awards program for entrepreneurs.

The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement.

As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.

Congratulations Joe!

Delivra Corp. manufactures and sells a growing line of natural topical creams with the proprietary transdermal delivery system platform under the LivRelief™ brand, for conditions such as joint and muscle pain, nerve pain, varicose veins, wound healing, and under the LivSport™ brand for sports performance. LivRelief™ products are available in pharmacies, grocery chains, and independent health food stores across Canada, and in the United States on-line. In parallel, Delivra also has a mandate to license its patent-pending proprietary transdermal delivery technology platform to pharmaceutical companies globally, for the transdermal delivery of repurposing Rx molecules to treat a broad range of conditions, along with licensing its over-the-counter products globally.

Mohammed Moin, co-founder of Emergence client, Somru BioScience Inc. from Charlottetown, PEI, has walked away with the 2018 EY Entrepreneur Of The Year award in the Health & Life Sciences category in the Atlantic region.

Mohammed Moin: Somru’s VP of Business Development

EY Entrepreneur Of The Year is the world’s most prestigious business awards program for entrepreneurs.

The program makes a difference through the way it encourages entrepreneurial activity among those with potential and recognizes the contribution of people who inspire others with their vision, leadership and achievement.

As the first and only truly global awards program of its kind, Entrepreneur Of The Year celebrates those who are building and leading successful, growing and dynamic businesses, recognizing them through regional, national and global awards programs in more than 145 cities in more than 60 countries.

Congratulations Moin!

Somru BioScience Inc. is an emerging biotechnology company dedicated to developing breakthrough antibody technology for research, diagnostic and therapeutic applications. The company currently uses antibodies to generate reagents that will accelerate biosimilar research and development.

Emergence client, Fredericton, New Brunswick-based Chinova Bioworks, has received its designation as GRAS (Generally Recognized as Safe) by an independent expert panel.

This designation is based on the U.S. Food and Drug Administration (FDA) requirements.

The GRAS determination applies exclusively to Chinova Bioworks’ mushroom chitosan preservative, and for specific uses that Chinova has designated.

Chinova Bioworks CEO, Natasha Dhayagude

“Having our Chiber™ mushroom chitosan ingredient recognized as GRAS allows us to commercialize our natural solution in the U.S. market for the first time,” Chinova CEO Natasha Dhayagude told us.

According to Dhayagude, “[GRAS status] demonstrates Chinova’s commitment to the highest standards of quality and safety of our ingredient.”

“This is an important milestone for us and an exciting development for our customers who are eager to replace artificial preservatives and make their foods and beverages healthy and clean label.”

Chinova’s Chiber™ is an antimicrobial food and beverage preservative made from a fiber extracted from mushrooms, called chitosan. It has the advantages of broad-spectrum antimicrobial effectiveness while being a healthy natural fiber.

About Chinova

Chinova Bioworks is a Canadian company that addresses the growing consumer demand for healthy, natural, clean-label ingredients, while providing producers with an effective solution that ensures food safety, shelf life, and the overall quality of the product. The company has developed an innovative preservative ingredient based on a fiber extracted from mushrooms called chitosan. This ingredient, Chiber™, offers broad-spectrum protection against all types of microorganisms (bacteria, yeast, and mold), is easy to use, and has no organoleptic impact, all at a competitive price point.

See also: Emergence client, Chinova Bioworks, raises US$2 million seed financing round and Emergence client, Chinova Bioworks, profiled by Rabobank